Kopran Limited Logo

Kopran Limited

KOPRAN.NS

(2.2)
Stock Price

323,85 INR

4.77% ROA

12.24% ROE

41.44x PER

Market Cap.

13.081.946.310,00 INR

21.11% DER

1.11% Yield

6.97% NPM

Kopran Limited Stock Analysis

Kopran Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kopran Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (17%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 ROE

ROE in an average range (7.91%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (4.54%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's PBV ratio (2.8x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Dividend

The company's history of regular dividend distributions in the last three years showcases its ability to generate reliable income for shareholders.

7 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (6.824), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

8 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Kopran Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kopran Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Kopran Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kopran Limited Revenue
Year Revenue Growth
2007 0
2008 1.186.325.000 100%
2009 1.643.592.000 27.82%
2010 1.947.754.000 15.62%
2011 1.989.044.951 2.08%
2012 2.502.162.423 20.51%
2013 3.028.470.321 17.38%
2014 3.257.269.148 7.02%
2015 2.963.191.362 -9.92%
2016 3.097.208.554 4.33%
2017 3.047.167.000 -1.64%
2018 3.487.620.000 12.63%
2019 3.503.992.000 0.47%
2020 4.814.864.000 27.23%
2021 4.742.772.000 -1.52%
2022 5.509.870.000 13.92%
2023 6.103.620.000 9.73%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kopran Limited Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 291.000 100%
2020 5.943.000 95.1%
2021 6.647.000 10.59%
2022 6.428.000 -3.41%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kopran Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 51.535.000 100%
2018 53.420.000 3.53%
2019 74.057.000 27.87%
2020 85.581.000 13.47%
2021 85.475.000 -0.12%
2022 91.475.000 6.56%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kopran Limited EBITDA
Year EBITDA Growth
2007 0
2008 61.164.000 100%
2009 184.951.000 66.93%
2010 233.725.000 20.87%
2011 268.080.789 12.82%
2012 339.777.784 21.1%
2013 433.954.821 21.7%
2014 320.659.657 -35.33%
2015 269.835.220 -18.84%
2016 446.366.354 39.55%
2017 386.549.000 -15.47%
2018 497.171.000 22.25%
2019 461.780.000 -7.66%
2020 990.679.000 53.39%
2021 962.437.000 -2.93%
2022 548.616.000 -75.43%
2023 918.308.000 40.26%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kopran Limited Gross Profit
Year Gross Profit Growth
2007 0
2008 413.562.000 100%
2009 627.987.000 34.14%
2010 704.796.000 10.9%
2011 719.927.293 2.1%
2012 960.184.920 25.02%
2013 1.151.060.777 16.58%
2014 1.138.378.449 -1.11%
2015 1.160.533.427 1.91%
2016 1.239.478.087 6.37%
2017 1.039.846.000 -19.2%
2018 1.284.321.000 19.04%
2019 1.301.860.000 1.35%
2020 1.671.900.000 22.13%
2021 1.901.722.000 12.08%
2022 1.924.232.000 1.17%
2023 2.335.332.000 17.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kopran Limited Net Profit
Year Net Profit Growth
2007 0
2008 137.893.000 100%
2009 4.751.000 -2802.4%
2010 48.602.000 90.22%
2011 53.398.130 8.98%
2012 111.187.413 51.97%
2013 171.781.381 35.27%
2014 -391.244.444 143.91%
2015 107.185.516 465.02%
2016 247.995.306 56.78%
2017 204.863.000 -21.05%
2018 240.230.000 14.72%
2019 210.202.000 -14.29%
2020 616.062.000 65.88%
2021 610.312.000 -0.94%
2022 272.330.000 -124.11%
2023 550.780.000 50.56%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kopran Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 4 100%
2009 0 0%
2010 1 100%
2011 1 0%
2012 3 50%
2013 4 50%
2014 -10 144.44%
2015 3 550%
2016 5 50%
2017 5 0%
2018 6 20%
2019 5 -25%
2020 14 71.43%
2021 14 -7.69%
2022 6 -160%
2023 11 54.55%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kopran Limited Free Cashflow
Year Free Cashflow Growth
2008 5.613.000
2009 9.657.000 41.88%
2010 139.523.000 93.08%
2011 241.379.646 42.2%
2012 60.814.912 -296.91%
2013 -63.871.231 195.21%
2014 350.187.227 118.24%
2015 176.367.550 -98.56%
2016 18.336.227 -861.85%
2017 142.884.000 87.17%
2018 -59.599.000 339.74%
2019 169.488.000 135.16%
2020 355.372.000 52.31%
2021 -757.470.000 146.92%
2022 -270.224.000 -180.31%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kopran Limited Operating Cashflow
Year Operating Cashflow Growth
2008 82.489.000
2009 34.723.000 -137.56%
2010 189.733.000 81.7%
2011 350.058.572 45.8%
2012 148.847.104 -135.18%
2013 27.876.094 -433.96%
2014 463.003.429 93.98%
2015 286.255.959 -61.74%
2016 179.512.846 -59.46%
2017 258.798.000 30.64%
2018 254.128.000 -1.84%
2019 310.018.000 18.03%
2020 599.513.000 48.29%
2021 -334.751.000 279.09%
2022 340.229.000 198.39%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kopran Limited Capital Expenditure
Year Capital Expenditure Growth
2008 76.876.000
2009 25.066.000 -206.69%
2010 50.210.000 50.08%
2011 108.678.926 53.8%
2012 88.032.192 -23.45%
2013 91.747.325 4.05%
2014 112.816.202 18.68%
2015 109.888.409 -2.66%
2016 161.176.619 31.82%
2017 115.914.000 -39.05%
2018 313.727.000 63.05%
2019 140.530.000 -123.25%
2020 244.141.000 42.44%
2021 422.719.000 42.25%
2022 610.453.000 30.75%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kopran Limited Equity
Year Equity Growth
2007 711.426.000
2008 654.183.000 -8.75%
2009 744.955.000 12.18%
2010 804.639.000 7.42%
2011 860.225.637 6.46%
2012 972.168.177 11.51%
2013 1.145.557.875 15.14%
2014 985.189.875 -16.28%
2015 1.087.154.373 9.38%
2016 1.334.710.309 18.55%
2017 1.447.083.000 7.77%
2018 1.684.757.000 14.11%
2019 1.896.800.000 11.18%
2020 2.450.304.000 22.59%
2021 4.261.689.000 42.5%
2022 4.392.457.000 2.98%
2023 4.414.258.000 0.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kopran Limited Assets
Year Assets Growth
2007 2.693.484.000
2008 2.358.849.000 -14.19%
2009 2.344.205.000 -0.62%
2010 2.321.937.000 -0.96%
2011 2.504.540.687 7.29%
2012 2.632.973.980 4.88%
2013 2.990.272.472 11.95%
2014 2.750.408.433 -8.72%
2015 2.637.925.529 -4.26%
2016 2.987.236.637 11.69%
2017 3.154.509.000 5.3%
2018 3.523.131.000 10.46%
2019 3.714.478.000 5.15%
2020 4.393.828.000 15.46%
2021 6.108.871.000 28.07%
2022 6.496.989.000 5.97%
2023 6.782.572.000 4.21%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kopran Limited Liabilities
Year Liabilities Growth
2007 1.982.057.000
2008 1.704.666.000 -16.27%
2009 1.599.250.000 -6.59%
2010 1.517.298.000 -5.4%
2011 1.644.315.050 7.72%
2012 1.660.805.803 0.99%
2013 1.844.714.597 9.97%
2014 1.765.218.558 -4.5%
2015 1.550.771.156 -13.83%
2016 1.652.526.328 6.16%
2017 1.707.426.000 3.22%
2018 1.838.374.000 7.12%
2019 1.817.677.000 -1.14%
2020 1.943.524.000 6.48%
2021 1.847.182.000 -5.22%
2022 2.104.532.000 12.23%
2023 2.368.314.000 11.14%

Kopran Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
120.05
Net Income per Share
6.55
Price to Earning Ratio
41.44x
Price To Sales Ratio
2.26x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
2.96
EV to Sales
2.42
EV Over EBITDA
22.53
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0.02
FreeCashFlow Yield
0
Market Cap
13,08 Bil.
Enterprise Value
14,00 Bil.
Graham Number
116.23
Graham NetNet
-6.7

Income Statement Metrics

Net Income per Share
6.55
Income Quality
0
ROE
0.14
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0.76
EBT Per Ebit
0.91
Ebit per Revenue
0.1
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.36
Operating Profit Margin
0.1
Pretax Profit Margin
0.09
Net Profit Margin
0.07

Dividends

Dividend Yield
0.01
Dividend Yield %
1.11
Payout Ratio
0
Dividend Per Share
3

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.07
Return on Tangible Assets
0.05
Days Sales Outstanding
108.3
Days Payables Outstanding
96.84
Days of Inventory on Hand
129.4
Receivables Turnover
3.37
Payables Turnover
3.77
Inventory Turnover
2.82
Capex per Share
0

Balance Sheet

Cash per Share
1,62
Book Value per Share
91,69
Tangible Book Value per Share
88.08
Shareholders Equity per Share
91.69
Interest Debt per Share
20.97
Debt to Equity
0.21
Debt to Assets
0.14
Net Debt to EBITDA
1.47
Current Ratio
2.01
Tangible Asset Value
4,24 Bil.
Net Current Asset Value
1,71 Bil.
Invested Capital
0.21
Working Capital
2,05 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,86 Bil.
Average Payables
0,51 Bil.
Average Inventory
681245500
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kopran Limited Dividends
Year Dividends Growth
2020 2
2021 2 0%
2022 3 66.67%
2023 3 0%

Kopran Limited Profile

About Kopran Limited

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.

CEO
Mr. Surendra Shrikrishna Soman
Employee
902
Address
Parijat House
Mumbai, 400018

Kopran Limited Executives & BODs

Kopran Limited Executives & BODs
# Name Age
1 Mr. Sunil Sodhani
Company Secretary & Compliance Officer
70
2 Mr. Ajit Jain FCA
Chief Operating Officer
70
3 Mr. Surendra Shrikrishna Somani B.Com.
Executive Vice Chairman & MD
70
4 Mr. Basant Kumar Soni
Chief Financial Officer
70
5 Chandra M. Singhi
Director
70
6 Ms. Vandana Somani
Director
70
7 Rakesh Doshi
Director
70
8 Mr. Kamesh Venkata Bhamidipati
Executive Officer
70

Kopran Limited Competitors

Gufic Biosciences Limited Logo
Gufic Biosciences Limited

GUFICBIO.NS

(2.8)
Indoco Remedies Limited Logo
Indoco Remedies Limited

INDOCO.NS

(3.2)
Lyka Labs Limited Logo
Lyka Labs Limited

LYKALABS.NS

(1.2)
Marksans Pharma Limited Logo
Marksans Pharma Limited

MARKSANS.NS

(3.2)
Hikal Limited Logo
Hikal Limited

HIKAL.NS

(2.8)